Skip to content

Bruker BRKR Intangibles (Net)

Intangibles (Net) at other companies

Danaher logo
DanaherDHR
$17.17B-9.1%
TEC
Bio-TechneTECH
$319.07M-28.1%
WAT
Waters CorporationWAT
$8.78B+1,465%
Agilent Technologies logo
Agilent TechnologiesA
$407M-17.8%
Revvity logo
RevvityRVTY
$2.31B-10.3%
Illumina logo
IlluminaILMN
$430M+54.7%

Other financials

Income statement

See full
Revenue$823.4M+2.7%
Gross profit$379.8M-2.9%
Operating income$10.2M-67.9%
Net income$14.4M-17.2%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$137.6M-26.7%
Total debt$1.7B-20.9%
Total equity$2.5B+34.6%
Total assets$6.1B+3.3%

Cash flow

See full
Operating cash flow$71.2M+9.5%
CapEx$24.2M-6.9%
Free cash flow$47.0M+20.5%

Valuation

See full
Market cap$8.71B-13.2%
Enterprise value$10.25B-14.9%
P/S2.5×-0.4×

Profitability

See full
Gross margin45.3%-3.7pp
Operating margin1.3%-5.0pp
Net margin-0.6%-10.0pp
FCF margin1.5%-3.6pp

Returns & leverage

See full
Return on equity-1%-21.2pp
Debt / equity0.7×-0.5×
Current ratio1.6×0.0×

Where this comes from

Reported directly by Bruker in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The official record: Bruker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bruker's intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bruker's intangibles (net)?
Bruker (BRKR) reported intangibles (net) of $902.4M in Q1 2026.
How has Bruker's intangibles (net) changed year-over-year?
Bruker's intangibles (net) increased by 0.1% year-over-year, from $901.7M to $902.4M.
What is the long-term trend for Bruker's intangibles (net)?
Over 5 years (2020 to 2025), Bruker's intangibles (net) has grown at a 31.5% compound annual growth rate (CAGR), from $229.1M to $899.6M.
What does intangibles (net) mean?
The net value of non-physical assets like patents and trademarks acquired by the company.
How do you interpret intangibles (net)?
A steady or increasing balance suggests successful R&D or strategic acquisitions, while rapid amortization may signal the aging of core technology.
How does intangibles (net) compare across companies?
High intangible asset levels are standard for R&D-intensive firms in the life sciences sector.